Evidence map›Paper›PMID 38543204›Full record

ReviewPharmaceutics2024

Extracellular Vesicles in Therapeutics: A Comprehensive Review on Applications, Challenges, and Clinical Progress.

Jiyoung Goo, Yeji Lee, Jeongmin Lee, In-San Kim, Cherlhyun Jeong

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 3 pooled it
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Jiyoung GooKHU-KIST Department of Converging Science and Technology, Kyunghee University, Seoul 02447, Republic of Korea.
Yeji LeeChemical and Biological Integrative Research Center, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea.
Jeongmin LeeChemical and Biological Integrative Research Center, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea.
In-San KimChemical and Biological Integrative Research Center, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea.
Cherlhyun JeongChemical and Biological Integrative Research Center, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea.ORCID 0000-0002-7584-3059
Korea University · KRBio-Medical Science (South Korea) · KRKyung Hee University · KR

Funding

KIST Institutional Program 2V09840-23-P038 (ISK) and 2E33132 (CJ)Ministry of Health and Welfare HI22C1501Ministry of Health and Welfare RS-2023-00266133Ministry of Science and ICT . 2021-0-02076Ministry of Science and ICT 2023-00262155National Research Council of Science and Technology 2017R1A3B1023418National Research Foundation of Korea 2021R1A2C1095046
6 · The paper itself

Abstract

Small Extracellular Vesicles (sEVs) are typically 30-150 nm in diameter, produced inside cells, and released into the extracellular space. These vesicles carry RNA, DNA, proteins, and lipids that reflect the characteristics of their parent cells, enabling communication between cells and the alteration of functions or differentiation of target cells. Owing to these properties, sEVs have recently gained attention as potential carriers for functional molecules and drug delivery tools. However, their use as a therapeutic platform faces limitations, such as challenges in mass production, purity issues, and the absence of established protocols and characterization methods. To overcome these, researchers are exploring the characterization and engineering of sEVs for various applications. This review discusses the origins of sEVs and their engineering for therapeutic effects, proposing areas needing intensive study. It covers the use of cell-derived sEVs in their natural state and in engineered forms for specific purposes. Additionally, the review details the sources of sEVs and their subsequent purification methods. It also outlines the potential of therapeutic sEVs and the requirements for successful clinical trials, including methods for large-scale production and purification. Finally, we discuss the progress of ongoing clinical trials and the implications for future healthcare, offering a comprehensive overview of the latest research in sEV applications.

Indexed as

clinical trialEV applicationEV engineeringEV purificationEVsexosomeextracellular vesicleslarge scale productionsEVs

Identifiers

PMID38543204
PMCPMC10974516
OpenAlexW4392034010

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.